Breast cancer, one of the most prevalent malignancies among women globally, involves multiple mechanisms in its pathogenesis and progression. Clinical treatment continues to face challenges such as recurrence and metastasis. Ezhu (Curcumae Rhizoma), a traditional Chinese medicine for promoting blood circulation and resolving stasis, is warm in nature, with pungent and bitter flavors, and acts on the liver and spleen meridians. It contains various active components, including volatile oils, curcuminoids, and other compounds, and functions to break blood stasis, promote qi movement, eliminate accumulation, and relieve pain. Modern pharmacological studies have demonstrated that Curcumae Rhizoma and its active components exert anti-breast cancer effects through multiple mechanisms, such as inhibiting cell proliferation, inducing apoptosis, preventing tumor metastasis, suppressing angiogenesis, and regulating autophagy. According to traditional Chinese medicine theory, Curcumae Rhizoma addresses the pathogenesis of “qi stagnation and blood stasis, toxic accumulation and masses” by strongly activating blood circulation, dispersing stagnation, and resolving masses, thereby alleviating breast masses (including breast cancer) caused by phlegm-stasis binding and qi obstruction. In compound formulations, the efficacy of Curcumae Rhizoma can be enhanced through different herb pairings. For example, when combined with qi-tonifying herbs like Huangqi (Astragali Radix), it reinforces healthy qi to eliminate pathogens and reduces chemotherapy resistance. When paired with blood-activating and stasis-resolving herbs such as Sanleng (Sparganii Rhizoma), it enhances the effect of dispersing masses and combating toxins, reflecting the compatibility strategy of “simultaneously eliminating pathogens and reinforcing healthy qi”. This article reviews the pharmacological mechanisms and research progress of Curcumae Rhizoma and its active components in anti-breast cancer studies in recent years, aiming to provide references for further research and clinical applications in breast cancer treatment.
Key words
Curcumae Rhizoma
/
breast cancer
/
volatile oil
/
curcumin
/
promoting blood circulation to remove blood stasis
ZHANG Siyuan, YIN Yi, HAN Wentong, LI Huan, WANG Xiangqi.
Research progress on mechanism and application of Curcumae Rhizoma in treatment of breast cancer[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(6)
: 2419
-2432
.
DOI: 10.7501/j.issn.0253-2670.2026.06.033
Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments[J]. Int Immunopharmacol, 2020, 84: 106535. Giaquinto A N, Sung H, Newman L A, et al. Breast cancer statistics 2024[J]. CA A Cancer J Clin, 2024, 74(6): 477-495. Cao W, Chen H D, Yu Y W, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791. Lei S Y, Zheng R S, Zhang S W, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun, 2021, 41(11): 1183-1194. Rodin D, Glicksman R M, Hepel J T, et al. Early-stage breast cancer: A critical review of current and emerging practice[J]. Int J Radiat Oncol Biol Phys, 2024, 120(5): 1260-1272. 张蒙蒙, 施高凡, 程静, 等. 基于中药活性成分纳米递药系统协同治疗乳腺癌的应用进展[J]. 中国药学杂志, 2024, 59(12): 1082-1092. 刘一斐, 史云, 苏先芝, 等. 张锡纯妇科学术思想及用药特色浅析[J]. 中华中医药杂志, 2020, 35(7): 3568-3571. 孔红芳, 袁书同, 袁飞龙, 等. 莪术油注射液化学成分、药理作用和临床应用的研究进展[J]. 中草药, 2023, 54(12): 4053-4060. 梁恒, 邓家彬, 童珊珊, 等. 我国姜黄属植物的系统关系研究进展[J]. 分子植物育种, 2019, 17(11): 3695-3702. 中国药典[S]. 一部. 2020: 286. 林敬祯, 黄鼎, 谭勇, 等. 中药莪术本草考证[J]. 亚太传统医药, 2023, 19(3): 189-192. 郑勇凤, 汪蕾, 赵思蕾, 等. 应用自动质谱退卷积定性系统(AMDIS)和保留指数分析3种不同基原莪术的挥发油成分差异[J]. 中国中药杂志, 2016, 41(2): 257-263. 于梦婷, 童黄锦, 毛春芹, 等. 基于色泽量化与主要成分含量的不同基原莪术饮片质量识别研究[J]. 中国中药杂志, 2021, 46(6): 1393-1400. 魏巍, 王冰瑶. 莪术及其主要成分的药理作用研究进展[J]. 药物评价研究, 2022, 45(10): 2154-2160. 汪镇朝, 张海燕, 宋远斌, 等. 中药挥发油抗肿瘤作用机制及其研究进展[J]. 中国实验方剂学杂志, 2020, 26(24): 219-226. 华天琦, 刘宇灵, 林龙飞, 等. 莪术油化学成分、抗肿瘤作用及制剂研究进展[J]. 中国药房, 2024, 35(11): 1396-1402. 崔婷, 倪红, 刘娟, 等. 蓬莪术挥发油中倍半萜类化学成分及舒张子宫平滑肌活性[J]. 中草药, 2022, 53(14): 4265-4269. 高红宁, 殷奕, 毛春芹, 等. HPLC法测定不同产地醋莪术饮片中姜黄素、双去甲氧基姜黄素和去甲氧基姜黄素的含量[J]. 中国医药科学, 2021, 11(3): 67-70. 刘布鸣, 袁健童, 苏华, 等. 广西莪术成分、药效、分析和临床应用进展[J]. 广西科学, 2023, 30(6): 1037-1051. 赵芃钰, 任虹, 徐李缘, 等. 姜黄属中药多糖的药理活性及其作用机制研究进展[J]. 中草药, 2025, 56(14): 5276-5287. 李泽宇, 曹瑞, 郝二伟, 等. 广西莪术化学成分和药理作用的研究进展及其质量标志物(Q-Marker)预测分析[J]. 中草药, 2021, 52(15): 4687-4699. 延琪瑶, 闫朝阳, 王浩峰, 等. 两种莪术类药用植物姜黄素提取物对小鼠抗氧化活性研究[J]. 基因组学与应用生物学, 2020, 39(1): 225-231. 王柳萍, 梁灿明, 李月儿, 等. 广西莪术化学成分研究[J]. 广西中医药, 2016, 39(2): 78-80. Xiong X, Zheng L W, Ding Y, et al. Breast cancer: Pathogenesis and treatments[J]. Signal Transduct Target Ther, 2025, 10(1): 49. Yin Q N, Ma H D, Bamunuarachchi G, et al. Long non-coding RNAs, cell cycle, and human breast cancer[J]. Hum Gene Ther, 2023, 34(11/12): 481-494. 李海龙, 刘培, 高秀飞. 中药莪术提取物对人三阴性乳腺癌MDA-MB-231细胞增殖的影响[J]. 中华中医药学刊, 2014, 32(10): 2416-2418. Susanti N M P, Tjahjono D H. Cyclin-dependent kinase 4 and 6 inhibitors in cell cycle dysregulation for breast cancer treatment[J]. Molecules, 2021, 26(15): 4462. 周璐炜, 王娟, 陈旭. 莪术醇抗T47D乳腺癌细胞增殖的作用机制研究[J]. 中国药房, 2022, 33(5): 548-554. Razavipour S F, Yoon H, Jang K, et al. C-terminally phosphorylated p27 activates self-renewal driver genes to program cancer stem cell expansion, mammary hyperplasia and cancer[J]. Nat Commun, 2024, 15(1): 5152. 马春兰, 张宝亮, 张常虹. 莪术醇对乳腺癌细胞增殖凋亡及JAK2/STAT3信号通路的影响[J]. 肿瘤学杂志, 2020, 26(7): 616-620. Sarkar R, Biswas S, Ghosh R, et al. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer[J]. J Nanobiotechnology, 2024, 22(1): 285. Hashemi M, Arani H Z, Orouei S, et al. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions[J]. Biomed Pharmacother, 2022, 155: 113774. Duong H Q, Kafer G, Maugham-Macan M. Bone metastasis in endocrine-related cancer: Unravelling invasion and destruction[J]. Endocr Relat Cancer, 2025, 32(2): e240294. Jamaludin S Y N, Azimi I, Davis F M, et al. Assessment of CXC ligand 12-mediated calcium signalling and its regulators in basal-like breast cancer cells[J]. Oncol Lett, 2018, 15(4): 4289-4295. 钱祥, 甄宏德, 李永峰, 等. 莪术石油醚提取物对三阴性乳腺癌细胞MDA-MB-231转移相关基因影响的体外研究[J]. 浙江中西医结合杂志, 2017, 27(6): 463-466. Gallardo M, Kemmerling U, Aguayo F, et al. Curcumin rescues breast cells from epithelial-mesenchymal transition and invasion induced by anti-miR-34a[J]. Int J Oncol, 2020, 56(2): 480-493. Devignes C S, Aslan Y, Brenot A, et al. HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice[J]. Proc Natl Acad Sci USA, 2018, doi: 10.1073/pnas.1718009115. 王丽莎, 夏欣欣, 李萍萍, 等. 莪术醇对乏氧微环境中人乳腺癌细胞株MCF-7生长转移机制的研究[J]. 中华中医药学刊, 2024, 42(12): 164-170. Li F F, Qi Q, Qiao Y, et al. Curcumenol inhibits malignant progression and promotes ferroptosis via the SLC7A11/NF-κB/TGF-β pathway in triple-negative breast cancer[J]. Int J Mol Med, 2025, doi: 10.3892/ijmm. 2025.5552. Argote Camacho A X, González Ramírez A R, Pérez Alonso A J, et al. Metalloproteinases 1 and 3 as potential biomarkers in breast cancer development[J]. Int J Mol Sci, 2021, 22(16): 9012. 孙学然, 杨克, 吕玲玲, 等. 莪术二酮对乳腺癌HCC1937细胞迁移和侵袭的影响及机制[J]. 中国实验方剂学杂志, 2019, 25(3): 66-73. Qian J Y, Zhao L N, Xu L, et al. Cell death: Mechanisms and potential targets in breast cancer therapy[J]. Int J Mol Sci, 2024, 25(17): 9703. Hao Q, Chen J X, Lu H, et al. The ARTS of p53-dependent mitochondrial apoptosis[J]. J Mol Cell Biol, 2023, 14(10): mjac074. 郭芳, 黎莉莉, 臧林泉. 莪术醇通过下调Bcl-2蛋白表达介导抗乳腺癌的机制研究[J]. 中国临床药理学杂志, 2018, 34(10): 1175-1178. Papadaki M A, Papadaki E, Chatziavraam S, et al. Prognostic value of fas/fas ligand expression on circulating tumor cells (CTCs) and immune cells in the peripheral blood of patients with metastatic breast cancer[J]. Cancers, 2024, 16(17): 2927. Vitale I, Pietrocola F, Guilbaud E, et al. Apoptotic cell death in disease-Current understanding of the NCCD 2023[J]. Cell Death Differ, 2023, 30(5): 1097-1154. 蒲磊, 赵树鹏. 莪术油对人乳腺癌MCF-7细胞增殖及凋亡的影响[J]. 中国新药与临床杂志, 2009, 28(5): 376-379. Calaf G M, Ponce-Cusi R, Carrión F. Curcumin and paclitaxel induce cell death in breast cancer cell lines[J]. Oncol Rep, 2018, 40(4): 2381-2388. Andolino C, Cotul E K, Xianyu Z, et al. Fatty acid synthase-derived lipid stores support breast cancer metastasis[J]. Cancer Metab, 2025, 13(1): 35. Fan H J, Liang Y, Jiang B, et al. Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells[J]. Oncol Rep, 2016, 35(5): 2651-2656. Niklaus N J, Tokarchuk I, Zbinden M, et al. The multifaceted functions of autophagy in breast cancer development and treatment[J]. Cells, 2021, 10(6): 1447. Pang J L, Xu L S, Zhao Q, et al. Sodium cantharidate promotes autophagy in breast cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway[J]. Front Pharmacol, 2022, 13: 1000377. 亓新峰, 冯绪强, 王建凤. 莪术醇通过抑制PI3K/Akt/mTOR信号通路介导的自噬抑制乳腺癌细胞的增殖活性[J]. 山西大同大学学报: 自然科学版, 2023, 39(4): 72-77. Akkoç Y, Berrak Ö, Arısan E D, et al. Inhibition of PI3K signaling triggered apoptotic potential of curcumin which is hindered by Bcl-2 through activation of autophagy in MCF-7 cells[J]. Biomed Pharmacother, 2015, 71: 161-171. Obeagu E I. Hypoxia-driven angiogenesis in breast cancer mechanisms and therapeutic targets: A narrative review[J]. Ann Med Surg, 2025, 87(7): 4246-4254. Bae S Y, Kamalanathan K J, Galeano-Garces C, et al. Dissemination of circulating tumor cells in breast and prostate cancer: Implications for early detection[J]. Endocrinology, 2024, 165(4): bqae022. 宋爱莉, 许振国. 莪术油对大鼠乳腺癌癌前病变组织中VEGF mRNA表达的影响[J]. 中华中医药学刊, 2012, 30(4): 679-681. 刘晓菲, 宋爱莉, 李静蔚, 等. 莪术油对大鼠乳腺癌癌前病变MVD及相关调控因子VEGF/FLK表达的干预作用研究[J]. 中医药学报, 2011, 39(4): 19-21. Yang D J, Li Y H, Xing L, et al. Utilization of adipocyte-derived lipids and enhanced intracellular trafficking of fatty acids contribute to breast cancer progression[J]. Cell Commun Signal, 2018, 16(1): 32. Thulasiraman P, McAndrews D J, Mohiudddin I Q. Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells[J]. BMC Cancer, 2014, 14: 724. Rao Q, Yu H, Li R C, et al. Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9[J]. Fundam Clin Pharmacol, 2024, 38(1): 113-125. Li M J, Lin L, Guo T T, et al. Curcumin administered in combination with glu-GNPs induces radiosensitivity in transplanted tumor MDA-MB-231-luc cells in nude mice[J]. Biomed Res Int, 2021, 2021: 9262453. Kim J, Munster P N. Estrogens and breast cancer[J]. Ann Oncol, 2025, 36(2): 134-148. Clusan L, Ferrière F, Flouriot G, et al. A basic review on estrogen receptor signaling pathways in breast cancer[J]. Int J Mol Sci, 2023, 24(7): 6834. Lim M S, Choung S Y, Jeong K W. Germacrone inhibits estrogen receptor α-mediated transcription in MCF-7 breast cancer cells[J]. Phytother Res, 2016, 30(12): 2036-2043. Wei Z L, Juan W, Tong D, et al. Curcumol inhibits breast cancer growth via NCL/ERα36 and the PI3K/AKT pathway[J]. Food Funct, 2023, 14(2): 874-885. 张亚旭, 杨铭, 徐杰男. 唐汉钧治疗乳腺癌术后药对及药症关系的数据挖掘研究[J]. 辽宁中医杂志, 2020, 47(10): 24-28. 吴金娜, 韩向晖, 叶依依, 等. 桔梗配伍不同治则中药对乳腺癌肺转移的影响[J]. 癌症进展, 2013, 11(2): 159-167. 吴金娜, 韩向晖, 叶依依, 等. 桔梗配伍不同治则中药对乳腺癌肺转移模型小鼠Smad4、Samd7及TGF-β1的影响[J]. 中国中医药科技, 2013, 20(3): 247-249. 俞泓波, 刘胜, 胡啸明, 等. 桔梗配伍对乳腺癌肺转移细胞株的干预作用[J]. 上海中医药大学学报, 2016, 30(2): 52-56. 韩向晖, 叶依依, 郭保凤, 等. 桔梗皂苷D配伍不同中药有效成分对乳腺癌4T1和MDA-MB-231细胞增殖及侵袭的影响[J]. 中西医结合学报, 2012, 10(1): 67-75. 施江培, 张荣光, 顾笑妍, 等. 桔梗-莪术药对对口服纳米粒细胞摄取的影响及体外抑制乳腺癌转移作用的研究[J]. 中国中药杂志, 2023, 48(9): 2419-2425. Shi J P, Zhang R G, Wang Y, et al. Herb-nanoparticle hybrid system for improved oral delivery efficiency to alleviate breast cancer lung metastasis[J]. Int J Nanomedicine, 2024, 19: 7927-7944. 冷福玉, 杨柱, 龙奉玺, 等. 国医大师刘尚义治疗乳腺癌的用药特点分析[J]. 中医药导报, 2020, 26(3): 114-118. 冯豆豆, 骆小珊, 蒙雁云, 等. 基于网络药理学与组分配伍理论探讨鳖甲-莪术有效组分协同抗三阴性乳腺癌的作用及机制验证[J]. 中国药理学通报, 2025, 41(5): 950-959. 胡雅清, 陈腾祥, 张金娟, 等. 鳖甲-莪术药对含药血清对MCF-7人乳腺癌细胞的影响[J]. 中成药, 2020, 42(10): 2599-2605. 朱久龙, 谢青, 黄雅珍, 等. 鳖甲-莪术药对对TGF-β1诱导的MDA-MB-231细胞侵袭转移能力及其上皮间质转化的作用及机制[J]. 贵州医科大学学报, 2022, 47(11): 1264-1273. Ferreira L C, Arbab A S, Jardim-Perassi B V, et al. Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer[J]. Anticancer Agents Med Chem, 2015, 15(10): 1285-1296. 邓樱, 唐润伟, 卫菊, 等. “黄芪-莪术”药对通过PTEN与p-AKT对人乳腺癌细胞增殖的影响[J]. 世界中医药, 2021, 16(11): 1712-1716. 邓樱, 唐润伟, 卫菊, 等. 黄芪-莪术对人乳腺癌的抑制作用及其机制[J]. 山西医科大学学报, 2021, 52(3): 255-263. Xu G L, Geng D, Xie M, et al. Chemical composition, antioxidative and anticancer activities of the essential oil: Curcumae Rhizoma-Sparganii Rhizoma, a traditional herb pair[J]. Molecules, 2015, 20(9): 15781-15796. 刘雪婷, 孙小慧, 朱建敏, 等. 基于网络药理学和分子对接探究三棱-莪术抗乳腺癌的作用机制[J]. 山东科学, 2022, 35(5): 26-36. Liu X Y, Chang Y L, Wang X H, et al. An integrated approach to uncover anti-tumor active materials of Curcumae Rhizoma-Sparganii Rhizoma based on spectrum-effect relationship, molecular docking, and ADME evaluation[J]. J Ethnopharmacol, 2021, 280: 114439. Chang Y L, Xu G L, Wang X P, et al. Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae Rhizoma-Sparganii Rhizoma and the single herbs[J]. J Ethnopharmacol, 2020, 250: 112465. 闫明, 任璐璐, 任士珂. 益气养荣汤联合针灸对乳腺癌术后气血两虚证T淋巴细胞亚群及血清CGA、slCAM-1、GDF3水平的影响[J]. 中华中医药学刊, 2025, 43(10): 243-246. 骆小珊, 谢甦, 冯豆豆, 等. 薯蓣丸联合依维莫司对TGF-β1诱导三阴性乳腺癌细胞上皮间质转化的抑制作用[J]. 中成药, 2025, 47(7): 2190-2197. 车思阳, 殷东风, 高宏, 等. 乳岩宁对三阴乳腺癌荷瘤裸鼠Notch1信号通路的作用机制[J]. 中华中医药学刊, 2024, 42(6): 50-54. 陈静, 樊锐锋, 李威, 等. 扶正消岩汤抑制三阴性乳腺癌细胞增殖的机制研究[J]. 时珍国医国药, 2023, 34(2): 302-305. 毛幼儿, 刘曦, 贺凯, 等. 玄胡索散通过下调粒细胞集落刺激因子抑制脾脏髓源抑制细胞分化发挥抗乳腺癌作用[J]. 浙江大学学报: 医学版, 2023, 52(1): 88-100. 常磊, 卓至丽, 卢雯平, 等. 疏肝益肾方治疗乳腺癌内分泌耐药的临床观察及对外泌体miR-221的影响[J]. 北京中医药大学学报, 2022, 45(12): 1295-1302. 丁思奇, 吴雪卿, 邵士珺. 乳癌术后方通过SDF-1/CXCR4信号通路对4T1小鼠乳腺癌肺转移的影响[J]. 中华中医药杂志, 2022, 37(6): 3574-3577. 张一君, 马海珍, 王展海. 抗癌扶正方联合化疗治疗转移性三阴性乳腺癌的临床观察[J]. 中国老年学杂志, 2021, 41(6): 1170-1173. 丁恒一, 高萍, 王建新. 益气安神汤对气血两虚型乳腺癌疗效及血清HER-2变化的研究[J]. 中华中医药学刊, 2020, 38(10): 127-130. 张洋, 刘晓菲, 朱晴, 等. 网络药理学指导下的疏肝健脾饮治疗乳腺癌作用机制探讨[J]. 中药材, 2019, 42(8): 1876-1884. 赵新月, 王桂彬, 司徒红林, 等. 林毅病-证-症结合辨治巩固期乳腺癌经验[J]. 中医杂志, 2024, 65(1): 26-30. 张亚旭, 杨铭, 徐杰男. 唐汉钧治疗乳腺癌术后药对及药症关系的数据挖掘研究[J]. 辽宁中医杂志, 2020, 47(10): 24-28. 童新, 金洋, 金晶, 等. 离线全二维逆流色谱-液相色谱分离莪术油成分[J]. 色谱, 2023, 41(12): 1115-1120. 郭明鑫, 马德翊, 李文静, 等. 气质联用法测定莪术油多效应成分及其在大鼠体内的整合药动学研究[J]. 中国药房, 2018, 29(20): 2752-2757.
PDF下载
全屏
26
10
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
